ChoA Pharmaceutical Co.Ltd (034940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ChoA Pharmaceutical Co.Ltd (034940) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.41 Billion ≈ $-1.63 Million USD) by net assets (₩21.62 Billion ≈ $14.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ChoA Pharmaceutical Co.Ltd to measure how much of total assets are equity-financed.
ChoA Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how ChoA Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 034940 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
ChoA Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ChoA Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mcphersons Ltd
AU:MCP
|
0.083x |
|
17 Education Technology Group Inc
NASDAQ:YQ
|
-1.269x |
|
Pinnacle Food Group Limited Class A Common Shares
NASDAQ:PFAI
|
N/A |
|
Cowell Development Tbk
JK:COWL
|
0.138x |
|
Tartisan Nickel Corp
F:8TA
|
-0.055x |
|
Managepay Systems Bhd
KLSE:0156
|
-0.040x |
|
Spirent Communications plc
LSE:SPT
|
0.039x |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
-0.291x |
Annual Cash Flow Conversion Efficiency for ChoA Pharmaceutical Co.Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of ChoA Pharmaceutical Co.Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see ChoA Pharmaceutical Co.Ltd (034940) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩21.77 Billion ≈ $14.75 Million |
₩-4.18 Billion ≈ $-2.83 Million |
-0.192x | -34.84% |
| 2024-12-31 | ₩31.38 Billion ≈ $21.26 Million |
₩-4.47 Billion ≈ $-3.03 Million |
-0.142x | -274.13% |
| 2023-12-31 | ₩38.76 Billion ≈ $26.27 Million |
₩-1.48 Billion ≈ $-999.75K |
-0.038x | -39.39% |
| 2022-12-31 | ₩52.84 Billion ≈ $35.81 Million |
₩-1.44 Billion ≈ $-977.89K |
-0.027x | +7.92% |
| 2021-12-31 | ₩49.92 Billion ≈ $33.83 Million |
₩-1.48 Billion ≈ $-1.00 Million |
-0.030x | -189.97% |
| 2020-12-31 | ₩58.30 Billion ≈ $39.51 Million |
₩1.92 Billion ≈ $1.30 Million |
0.033x | -57.93% |
| 2019-12-31 | ₩53.06 Billion ≈ $35.96 Million |
₩4.16 Billion ≈ $2.82 Million |
0.078x | +106.82% |
| 2018-12-31 | ₩53.96 Billion ≈ $36.57 Million |
₩2.04 Billion ≈ $1.39 Million |
0.038x | +403.82% |
| 2017-12-31 | ₩54.18 Billion ≈ $36.71 Million |
₩-675.51 Million ≈ $-457.78K |
-0.012x | -164.11% |
| 2016-12-31 | ₩47.84 Billion ≈ $32.42 Million |
₩930.42 Million ≈ $630.53K |
0.019x | -22.74% |
| 2015-12-31 | ₩47.15 Billion ≈ $31.96 Million |
₩1.19 Billion ≈ $804.48K |
0.025x | +85.49% |
| 2014-12-31 | ₩46.09 Billion ≈ $31.23 Million |
₩625.52 Million ≈ $423.90K |
0.014x | -80.55% |
| 2013-12-31 | ₩50.63 Billion ≈ $34.31 Million |
₩3.53 Billion ≈ $2.39 Million |
0.070x | -68.88% |
| 2004-12-31 | ₩15.94 Billion ≈ $10.81 Million |
₩3.57 Billion ≈ $2.42 Million |
0.224x | -- |
About ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more